Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 17/11/2017
SIETES contiene 92128 citas

 
 
 1 a 20 de 264 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Lemaitre M, Kirchgesner J, Rudnichi A, Carrat F, Zureik M, Carbonnel F, Dray-Spira R. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA 2017;318:1679-86. [Ref.ID 102138]
2. Cita con resumen
Anónimo. Inflectra - An infliximab biosimilar. Med Lett Drugs Ther 2017;59:23-5. [Ref.ID 101422]
3. Cita con resumen
Anónimo. Ustekinumab (Stelara) for Crohn's disease. Med Lett Drugs Ther 2017;59:5-6. [Ref.ID 101387]
4. Cita con resumen
Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao L-L, MIao Y, Adedokun OJ, Sands BE, Hanauer SB, Vermeire S, Targan S, Ghosh S, de Villiers WJ, Colombel J-F, Tulassay Z, Seidler U, Salzberg BA, Desreumaux P, Lee SD, Loftus EV, Dieleman LA, Katz S, Rutgeerts P, for the UNITI-IM-UNITI Study Group. Ustekinumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2016;375:1946-60. [Ref.ID 100991]
5. Cita con resumen
Anónimo. FDA approves ustekinumab for adults with moderate to severe Crohn’s. DIA Daily 2016:2. [Ref.ID 100758]
6. Cita con resumen
Anónimo. EMA committee recommends approval of ustekinumab for Crohn’s. DIA Daily 2016:2. [Ref.ID 100685]
7. Cita con resumen
Hawkey CJ, Allez M, Clark MM, Labopin M, Lindsay JO, Ricart E, Rogler G, Rovira M, Satsangi J, Danese S, Russell N, Gribben J, Johnson P, Larghero J, Thieblemont C, Ardizzone S, Dierickx D, Ibatici A, Littlewood T, Onida F, Schanz U, Vermeire S, Colombel J-F, Jouet J-P, Clark E, Saccardi R, Tyndall A, Travis S, Farge D. Autologous hepatopoetic stem cell transplantation for refractory Crohn disease: a randomized clinical trial. JAMA 2015;314:2524-34. [Ref.ID 99796]
8. Cita con resumen
Khanna R, Bressler B, Levesque BG, Zou G, Sitt LW, Greenberg GR, Panaccione R, Bitton A, Paré P, Vermeire S, D'Haens G, Macintosh D, Sandborn WJ, Donner A, Vandervoort MK, Morris JC, Feagan BG, REACT Study Investigators. Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial. Lancet 2015;386:1825-34. [Ref.ID 99669]
9. Cita con resumen
McCall C. Momentum grows for medical use of cannabis. Lancet 2015;386:1615-6. [Ref.ID 99633]
10. Cita con resumen
Anónimo. Védolizumab. Prescrire 2015;35:263-4. [Ref.ID 99125]
11.Tiene citas relacionadas Cita con resumen
De Cruz P, Kamm MA, Hamilton AL, Ritchie KJ, Krejany EO, Gorelik A, Liew D, Prideaux L, Lawrance IC, Andrews JM, Bampton PA, Gibson PR, Sparrow M, Leong RW, Florin TH, Gearry RB, Radford-Smith G, Macrae FA, Debinski H, Selby W, Kronborg I, Johnston MJ, Woods R, Elliott PR, Bell SJ, Brown SJ, Connell WR, Desmond PV. Crohn's disease management after intestinal resection: a randomised trial. Lancet 2015;385:1406-17. [Ref.ID 99034]
12.Tiene citas relacionadas
Ananthakrishnan AN. Surgery for Crohn's disease: look harder, act faster. Lancet 2015;385:1370-1. [Ref.ID 99031]
13. Cita con resumen
Anónimo. Vedolizumab (Entyvio) for inflammatory bowel disease. Med Lett Drugs Ther 2014;56:86-8. [Ref.ID 98222]
14. Cita con resumen
Anónimo. Drugs for inflammatory bowel disease. Med Lett Drugs Ther 2014;56:59-66. [Ref.ID 98172]
15.Enlace a cita original
16. Cita con resumen
Anónimo. Antibiotiques dans l'enfance et maladie intestinale inflammatoire?. Prescrire 2014;34:354-5. [Ref.ID 97563]
17. Cita con resumen
Anónimo. Medicine to treat colitis, Crohn’s disease gets FDA nod. DIA Daily 2014:21 de mayo. [Ref.ID 97520]
19. Cita con resumen
Anónimo. TNF inhibitors for Crohn's disease: when, which, and for how long. Med Lett Drugs Ther 2013;55:102-3. [Ref.ID 96731]
20. Cita con resumen
Lazzerini M, Martelossi S, Magazzù G, Pellegrino S, Lucanto MC, Barabino A, Calvi A, Arrigo S, Lionetti P, Lorusso M, Mangiantini F, Fontana M, Zuin G, Palla G, Maggiore G, Bramuzzo M, Pellegrin MC, Maschio M, Villanacci V, Manenti S, Decorti G, De Iudicibus S, Paparazzo R, Montico M, Ventura A. Effect of thalidomide on clinical remission in children and adolescents with refractory Crohn disease: a randomized clinical trial. JAMA 2013;310:2164-73. [Ref.ID 96603]
Seleccionar todas
 
 1 a 20 de 264 siguiente >>